2024
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study
Iyer S, Sica R, Ho P, Prica A, Zain J, Foss F, Hu B, Beitinjaneh A, Weng W, Kim Y, Khodadoust M, Huen A, Williams L, Ma A, Huang E, Ganpule A, Nagar S, Sripakdeevong P, Cullingford E, Karnik S, Dequeant M, Patel J, He X, Li Z, He Q, Mendonez J, Keegan A, Horwitz S. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. The Lancet Oncology 2024 PMID: 39617017, DOI: 10.1016/s1470-2045(24)00508-4.Peer-Reviewed Original ResearchT-cell lymphomaPeripheral T-cell lymphomaCutaneous T-cell lymphomaRefractory T-cell lymphomaEastern Cooperative Oncology GroupChimeric antigen receptorCytokine release syndromeCAR+ T cellsSerious adverse eventsAdverse eventsT cellsOpen-labelRefractory peripheral T-cell lymphomaAllogeneic chimeric antigen receptorHealthy donor T cellsRefractory T-cell malignanciesCAR-T cell therapyMedian patient follow-upIncidence of adverse eventsDonor T cellsObjective response rateSystemic therapy linesDose-limiting toxicityT-cell therapyDose-escalation studyDevelopment of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium
Koh M, Han J, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Kim J, Kim Y, Cho J, Eipe T, Shet T, Sridhar E, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al Mansour M, Ford J, Manni M, Civallero M, Skrypets T, Federico M, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Development of a Novel Prognostic Score for Relapsed/Refractory Mature T-Cell and NK-Cell Lymphomas (PIRT): Results from a Global Peripheral T-Cell Lymphoma (PETAL) Consortium. Blood 2024, 144: 465. DOI: 10.1182/blood-2024-201874.Peer-Reviewed Original ResearchNK-cell lymphomasMature T cellsMultivariate Cox regressionCytotoxic chemotherapyOverall survivalNK cellsT cellsAssociated with inferior OSPeripheral T-cell lymphomaInternational retrospective cohort studySecond-line treatmentT-cell lymphomaRetrospective cohort studyIdentification of risk factorsR/R patientsInferior OSPrognostic factorsPrognostic scorePrognostic valueTreatment detailsHighest concordance indexUnivariate analysisDiagnosed patientsConcordance indexC-indexSpatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma
Enninful A, Foss F, Fan R, Xu M. Spatial Multiomics Profiling of Angioimmunoblastic T-Cell Lymphoma. Blood 2024, 144: 1585-1585. DOI: 10.1182/blood-2024-211129.Peer-Reviewed Original ResearchAngioimmunoblastic T-cell lymphomaT follicular helper cellsT-cell lymphomaFollicular dendritic cellsHigh endothelial venulesT cellsTumor cellsTumor microenvironmentB cellsImmune surveillanceMultiplex immunofluorescenceCD21+ follicular dendritic cellsTumor evasion of immune surveillanceNon-neoplastic T cellsEvasion of immune surveillanceEBV-positive B cellsGene activity scoreTissue blocksActivity of tumor cellsReactive B cellsExpression of LMP1Positive B cellsComplex tumor microenvironmentT cell zonesLymph node samplingSurvival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort
Braunstein Z, McLaughlin E, Lingamaneni P, Barta S, Cao M, Chang T, Ganesan N, Luu B, Mehta-Shah N, Shree T, Watkins M, Zain J, Allen P, Paulino D, Adams B, Wang J, Feng A, Marchi E, Roberts N, Wilcox R, Gutierrez M, Frosch Z, Sklarz T, Sethi T, Foss F, Beaven A, Haverkos B, Treitman R, Stevens P, Mishra A, Stuver R, Hampel P, Brammer J. Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort. Blood 2024, 144: 982-982. DOI: 10.1182/blood-2024-194242.Peer-Reviewed Original ResearchT-cell prolymphocytic leukemiaProgression-free survivalOverall survivalMedian OSFrontline treatmentT-PLL patientsTherapeutic outcomesMedian follow-up timeT-cell prolymphocytic leukemia cellsResponse rateCompared to CD4Multi-center seriesVenetoclax-based regimensSecond-line treatmentKaplan-Meier methodFollow-up timeSubgroup survival analysisCox proportional hazards modelsComprehensive clinical dataMulti-center studyProportional hazards modelFrontline therapyNodal involvementResponding patientsT-PLLGene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating tumor cellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletionClinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment
Kiwan A, Kewan T, Bravo-Perez C, Visconte V, Gurnari C, Durmaz A, Siddon A, Halene S, Sethi T, Maciejewski J, Foss F. Clinically Driven Algorithms Identify Patients with Large Granular Lymphocytic Leukemia at Risk of Significant Cytopenia Requiring Treatment. Blood 2024, 144: 4436. DOI: 10.1182/blood-2024-209344.Peer-Reviewed Original ResearchT-cell rearrangementArea under the curveGranular lymphocytic leukemiaMonoclonal gammopathyUnivariate analysisRheumatoid arthritisMyelodysplastic syndromeClonal hematopoiesisMedian ageLymphocytic leukemiaFactors associated with anemiaAbsence of CD4Associated with cytopeniaHistory of rheumatoid arthritisAssociated with neutropeniaExpression of CD5Presence of splenomegalyTreatment requirementsAssociated with anemiaMultivariate logistic regression modelPrimary etiological factorMultivariate regressionPersonalized treatment strategiesUnivariate logistic regressionAssociated with treatmentAsparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study
Allen P, Bagley E, Graf K, Sethi T, Foss F, Dong N, Saeed H, Wang J, Dittus C, Paulino D, Wilcox R, Barta S, Carvajal V, Mehta-Shah N, Mou E, Ravindra A, Haverkos B, Mehta A, Shea L, Zain J, Reef D, Ayzman A, Greenwell I. Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study. Blood 2024, 144: 1690. DOI: 10.1182/blood-2024-211424.Peer-Reviewed Original ResearchExtranodal NK/T-cell lymphomaNK/T-cell lymphomaAsparaginase useENKTL patientsResponse rateTreatment patternsDiscontinued due to toxicityMulticenter retrospective cohort studyNon-ASP groupAssociated with significant ratesTherapy related deathsEBV-associated lymphomasKaplan-Meier methodCox proportional hazards regressionRetrospective cohort studyQuarter of patientsProportional hazards regressionStatistically significant advantageHigh response rateLimitations of therapyAnalysis of outcomesAssociated lymphomaChemotherapy backboneNeutropenic feverAsparaginase dosesOutcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients
Qureshi H, Kiwan A, Foss F, Kothari S, Huntington S, Isufi I, Seropian S, Sethi T. Outcome of an Urban Cohort of North American Adult T-Cell Leukemia/Lymphoma Patients. Blood 2024, 144: 6421-6421. DOI: 10.1182/blood-2024-211850.Peer-Reviewed Original ResearchAdult T-cell leukemia/lymphomaWhite blood cellsProgression free survivalWhite blood cell countOverall survivalHuman immunodeficiency virusComplete responseProgressive diseaseATLL patientsHD-MTXInstitutional cohortResponse to first line therapyAdult T-cell leukemia/lymphoma patientsMultivariate analysisMedian progression free survivalMedian time to relapseAllogeneic stem cell transplantationHuman T-cell lymphotropic virus type 1Median age of diagnosisMedian white blood cellMedian overall survivalHigh-dose methotrexateMulti-agent chemotherapyFirst line therapyMedian follow-upGlobal outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium
Han J, Koh M, Boussi L, Sorial M, McCabe S, Peng L, Singh S, Eche-Ugwu I, Gabler J, Fernandez Turizo M, MacVicar C, Garg A, Disciullo A, Chopra K, Lenart A, Nwodo E, Barnes J, Koh M, Miranda E, Chiattone C, Stuver R, Horwitz S, Merrill M, Jacobsen E, Manni M, Civallero M, Skrypets T, Lymboussaki A, Federico M, Kim Y, Kim J, Cho J, Eipe T, Shet T, Epari S, Shetty A, Saha S, Jain H, Sengar M, Van Der Weyden C, Prince H, Hamouche R, Muradashvili T, Foss F, Gentilini M, Casadei B, Zinzani P, Okatani T, Yoshida N, Yoon S, Kim W, Panchoo G, Mohamed Z, Verburgh E, Alturas J, Al-Mansour M, Ford J, Cabrera M, Ku A, Bhagat G, Ma H, Sawas A, Kariya K, Iwasaki M, Bhanushali F, O'Connor O, Marchi E, Shen C, Shah D, Jain S. Global outcomes and prognosis for relapsed/refractory mature T-cell and NK-cell lymphomas: Results from PETAL consortium. Blood Advances 2024 PMID: 39481087, DOI: 10.1182/bloodadvances.2024014674.Peer-Reviewed Original ResearchNK-cell lymphomasOverall survivalMature T cellsALK-ALCLNK cellsT cellsAssociated with 3-year OSTiming of second-line treatmentSuperior median overall survivalMedian overall survivalPrimary refractory diseaseProgression-free survivalInternational retrospective cohort studySecond-line treatmentEfficacy of novel drugsIdentified several independent predictorsRetrospective cohort studyR/R lymphomaExtranodal sitesPTCL-NOSIntermediate-riskCytotoxic chemotherapyHistological subtypesRefractory diseaseRelapsed lymphomaReal World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma
Straining R, Foss F, Schiffer M, Amin K, Agarwal S, Isufi I, Huntington S, Kothari S, Seropian S, Girardi M, Sethi T. Real World Data on Efficacy and Safety of EPOCH in T-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia 2024 PMID: 39368885, DOI: 10.1016/j.clml.2024.09.005.Peer-Reviewed Original ResearchT-cell lymphomaHeterogeneous group of lymphoid malignanciesGroup of lymphoid malignanciesPeripheral T-cell lymphomaAggressive T-cell lymphomaCutaneous T-cell lymphomaT cellsResponse rateR/R settingComplete responseLymphoid malignanciesPoor outcomeAnaplastic large cell lymphomaFrontline treatment regimensLarge cell lymphomaCombination of prednisoneHeterogeneous groupCell lymphomaChemotherapy optionsCaucasian patientsFirst-linePositive patientsTreatment regimensGrade 3LymphomaClinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas
Swallow M, Micevic G, Zhou A, Carlson K, Foss F, Girardi M. Clinical and Histologic Variants of CD8+ Cutaneous T-Cell Lymphomas. Cancers 2024, 16: 3087. PMID: 39272944, PMCID: PMC11394026, DOI: 10.3390/cancers16173087.Peer-Reviewed Original ResearchT-cell lymphomaPrimary cutaneous gamma/delta T-cell lymphomaSubcutaneous panniculitis-like T-cell lymphomaLymphoproliferative disordersMycosis fungoidesCD8+ cutaneous T-cell lymphomasCutaneous gamma/delta T-cell lymphomaPanniculitis-like T-cell lymphomaGamma/delta T-cell lymphomaCytotoxic T-cell lymphomaT-cell lymphoproliferative disorderAbnormal T-cell populationCutaneous T-cell lymphomaCytotoxic molecule expressionT cell populationsIndicator of prognosisAppropriate treatment planCD8-positiveAggressive entityLymphomatoid papulosisHistological variantsHistopathological differentiationTreatment algorithmCD8Clinical manifestationsValemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Inoue A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s229. DOI: 10.1016/s2152-2650(24)00908-x.Peer-Reviewed Original ResearchTCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial
Maruyama D, Porcu P, Tobinai K, Allen P, Ishitsuka K, Tsukasaki K, Kusumoto S, Narita T, Foss F, Yamauchi N, Yuda J, Morishima S, Imaizumi Y, Izutsu K, Feldman T, Kawamata T, Kakurai Y, Yamauchi H, Biserna N, Maruyama A, Tachibana M, Hizukuri Y, Horwitz S, Jacobsen E. TCL-391 Valemetostat Monotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas: Primary Results From a Phase 1 Trial. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s523-s524. DOI: 10.1016/s2152-2650(24)01617-3.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsB-NHLR/R NHLPartial responseEZH2 mutationsAdverse eventsMedian duration of responseRecommended phase 2 doseRelapsed/refractory non-Hodgkin lymphomaTreatment-related adverse eventsPhase 2 doseR/R follicular lymphomaNon-Hodgkin's lymphomaDuration of responseMaximum tolerated doseDecreased platelet countPhase 1 trialYears of ageFollicular lymphomaTolerated doseDose reductionOpen-labelMedian durationEfficacy analysisMedian ageP-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM)
Theprungsirikul P, Yu M, Liu Y, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. P-088 Evaluating T-cell Fitness Pre B-Cell Maturation Antigen (BCMA)-Targeted T-Cell Redirection Therapies (TRT) as a Predictive Marker for Efficacy/Toxicity in Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia 2024, 24: s92-s93. DOI: 10.1016/s2152-2650(24)01991-8.Peer-Reviewed Original ResearchPhase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma
Witzig T, Sokol L, Kim W, de la Cruz Vicente F, GarcÃa-Sancho A, Advani R, Vidal J, de Oña Navarrete R, Marin-Niebla A, Izquierdo A, Terol M, Domingo-Domenech E, Saunders A, Bendris N, Mackey J, Leoni M, Foss F. Phase 2 trial of the farnesyltransferase inhibitor tipifarnib for relapsed/refractory peripheral T-cell lymphoma. Blood Advances 2024, 8: 4581-4592. PMID: 38991123, PMCID: PMC11401221, DOI: 10.1182/bloodadvances.2024012806.Peer-Reviewed Original ResearchRelapsed/refractory peripheral T-cell lymphomaAngioimmunoblastic T-cell lymphomaPeripheral T-cell lymphomaT-cell lymphomaProgression-free survivalDuration of responseAdverse eventsAngioimmunoblastic T-cell lymphoma patientsMedian duration of responseMedian progression-free survivalSafety of tipifarnibHematologic adverse eventsMedian overall survivalTreatment-related deathsBiomarkers of responsePhase 2 trialSixty-five patientsFarnesyltransferase inhibitor tipifarnibNon-responder groupTumor mutational profileSingle-arm trialPTCL-NOSOpen-labelOverall survivalPrimary endpoint572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma
Ren J, Liao X, Lewis J, Li D, Chang J, Swallow M, Lee J, Qu R, Carlson K, Foss F, Girardi M. 572 Development of immunotherapies targeting TCR-Vβ2 for treatment of cutaneous T cell lymphoma. Journal Of Investigative Dermatology 2024, 144: s100. DOI: 10.1016/j.jid.2024.06.588.Peer-Reviewed Original ResearchCosts of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas
Di M, Potnis K, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas. JNCI Cancer Spectrum 2024, 8: pkae059. PMID: 39115391, PMCID: PMC11340641, DOI: 10.1093/jncics/pkae059.Peer-Reviewed Original ResearchChimeric antigen receptor T-cell therapyB-cell lymphomaRelapsed/refractory B-cell lymphomaT-cell therapyCAR-T administrationCAR-T productsMedian total costCommercially insured patientsReal-world costsMedian costOut-of-pocket copaymentsCost of careLymphomaMonthly costTherapyPatientsProduct acquisitionFinancial outcomesHigher upfront costChart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019
Girardi M, Carlson K, Huang X, Corman S, Edmundson P, Schmier J, Kale H, Raina R, Foss F. Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017–2019. Journal Of Dermatological Treatment 2024, 35: 2360568. PMID: 38852942, DOI: 10.1080/09546634.2024.2360568.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsExtracorporeal photopheresisResponse rateClinical outcomesMonths of ECP treatmentMedian time to responseReal-world treatment patternsECP initiationLymph node involvementStage IV diseaseAdvanced-stage diseaseT-cell lymphomaTime to responseEffective treatment optionPercentage of patientsChart review studyIV diseaseSezary syndromeNode involvementConcomitant therapySystemic therapyMedian ageMycosis fungoidesChart reviewAssociations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM).
Theprungsirikul P, Yu M, Rall K, Matthews M, Neparidze N, Parker T, Browning S, Anderson T, Stevens E, Foss F, Gowda L, Pillai M, Isufi I, Seropian S, Mirza S, Bar N. Associations of T-cell fitness prior to B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor T-cell (CART) and bispecific T-cell engager (BiTE) therapies and efficacy/toxicity in relapsed/refractory multiple myeloma (RRMM). Journal Of Clinical Oncology 2024, 42: 7549-7549. DOI: 10.1200/jco.2024.42.16_suppl.7549.Peer-Reviewed Original ResearchChimeric antigen receptor T cellsRelapsed/refractory multiple myelomaT cell fitnessHigh-risk cytogeneticsCytokine release syndromeNon-respondersExtramedullary diseaseT cellsPeripheral blood prior to treatmentInternational Myeloma Working Group criteriaNR groupBlood prior to treatmentBispecific T-cell engagerMedian follow-up timeMedian prior linesT-cell therapyPost-treatment follow-upT-cell engagersT cell influxT-cell %Working Group criteriaYale Cancer CenterMann-Whitney U testResponse to disease progressionIdecabtagene vicleucelAllogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma
Goyal A, Foss F. Allogeneic transplantation and cellular therapies in cutaneous T-cell lymphoma. Expert Review Of Anticancer Therapy 2024, 24: 41-58. PMID: 38224371, DOI: 10.1080/14737140.2024.2305356.Peer-Reviewed Original ResearchConceptsDonor lymphocyte infusionTotal body irradiationT-cell lymphomaCAR-T cell therapyCutaneous T-cell lymphomaT-cell therapySezary syndromeAllo-HSCTT cellsLymphocyte infusionCAR-TMycosis fungoidesAllogeneic hematopoietic stem cell transplantationCAR-T cell persistenceReduced-intensity conditioning regimensHematopoietic stem cell transplantationAdvanced stage MFTemporary disease controlTreatment of MF/SSCAR-T therapyInduce complete remissionCurative treatment optionStem cell transplantationNonmalignant T cellsTime of transplantation